💥#EndometrialCancer TKI/IO safety data & AE mgmt webinar 💥┈┈┈ w @DrMMurphy & @drteplinsky ┈┈┈🔹#CME info 👉 bit.ly/3Vqtabi 👈 @BonumCE ┈┈┈🔸Supported by edu grants from Eisai & @Merck 🔹#TumorBoardTuesday #gyncsm #OncTwitter twitter.com/i/broadcasts/1… 1/#TumorBoardTuesday #OncTwitter

#1:Answer #PreTest❓🔗bit.ly/EC_AEs_TBTpre
#2:Tell us who u are👇
#3:🔁Retweet & tag colleagues

🧧#CME ℹ️bit.ly/3Vqtabi
Supported by edu grants from Eisai & @Merck

🟢Where r u in your career?

1/#TumorBoardTuesday #OncTwitter

🗓️TODAY🗓 w @DrMMurphy & @DrTeplinsky
🎥#EndometrialCancer - Mnging TKI/IO AEs

#CMEℹ️ bit.ly/3Vqtabi
Support by edu grants from Eisai & @Merck

🚨Be ready @ 8p ET/5p PT
✅Answer #PreTest👇
🔁RT & tag 🩺

🟢Where r u in your career? 2/#TumorBoardTuesday #OncTwitter #GynCSM #gynonc
#CME🔗bit.ly/3YRDkog

🟢#PreTest Q 1️⃣
📊Diarrhea, nausea, & vomiting are common GI toxicities associated w pembro + lenvatinib combo therapy

🟢Which other tox may occur if these GI toxicities are not effectively managed?

1/#OncTwitter #TumorBoardTuesday #MedTweetorial 🧵

✅#EndometrialCancer AE deep dive🤿
🧪Trial results
🔬Tox for TKI-ICI
w @DrMMurphy @MeganLeigh127 & us!

🆓#CME @BonumCe🔗bit.ly/3VBGJEJ
Supported by edu grants from Eisai & @Merck

🟢What's your specialty? 2/#TumorBoardTuesday #BonumCE #OncTwitter #gyncsm #gynonc #EndometrialCancer #MedTweetorial

🆓 CME > full info➕ref list🗒️& program archive
👉bit.ly/3VBGJEJ

🔑#CME info👇

@MPishvaian #GI23
Coming at you from #TumorBoardTuesday
The TOP 🎯💊abstracts for ASCO-GI 2023

➡️Starting with MSI-H cancers:
✅Path CR neoadj ICI MSI-H GI Cancers
👁️L Pappas, Abs 43, Pos B18

✅A Ph 2 trial of toripalimab in adv tumors with POLE/POLD1🧬mut
👁️Y Jin, Abs 802, Pos M17 @MPishvaian #GI23
➡️Exciting updates in HER2➕Cancers

✅A Ph 2 trial of trast➕pertuz vs. iri➕cetuximab for HER2➕mCRC: SWOG S1613
👁️KPS Raghav, Abs 140, Pos G18

✅Zanidatamab➕chemo as 1⃣st-line Tx for HER2➕met GE jxn AdenoCa
👁️Ea Elimova, Abs 347, Pos E8

1/🛎️#TumorBoardTuesday #OncTwitter #NephTwitter
#RenalCell wk continues🔁

🗓️Thu 12.15 @ 8p ET

⚙️Mnging AEs w TKI/IO combos

#CME ℹ️🔗bit.ly/3iLN6aX
Supported by edu grants from Eisai & @Merck
🚨Be ready 4 tmrw!
✅Answer #PreTest polls👇
🔁Retweet & tag colleagues🩺 2/ 🏆Claim 🆓#CME 🔛 bit.ly/3iLN6aX

Answer Pre Polls Qs 👇today
🟢Where r u in your career?

1/ #OncTwitter #NephTwitter #TumorBoardTuesday
✅#RenalCell #MedTweetorial🧵
w @brian_rini @shilpaonc @katy_beckermann

🦺TKI/IO safety data
🥽Tox to look 4
⛑AE mgmt

🆓#CME @BonumCe🔗bit.ly/3VDaK81
Support by edu grants from Eisai & @Merck

🟢What's your specialty? 2/ #TumorBoardTuesday #BonumCE #RenalCell #OncTwitter #NephTwitter
🆓#CME info ➕ full ref list🗒️ 👉 bit.ly/3VDaK81

✳️The critical elements👇

#TumorBoardTuesday #ASCO2022

📢@ASCO is only a few days away & we really wanted to put out our top abstracts to👀for

🙏note - we viewed several thousand titles - so we definitely may have missed some‼️
👉And these are not in any particular order

✅But enjoy, RT, and reply😀 #TumorBoardTuesday #ASCO2022
"Emerging"🎯💊
✅Dr. Jones👨‍🏫the Ph2 FAKTION trial of fulv/capi vs fulv/placebo for Breast Ca
➡️Capi⬆️mOS by 6 mos
➡️This⬆️jumped to 19 ms if the tumor harbored PIK3CA or AKT1 activating OR PTEN inactivating🧬mutations
🔎Breast Ca Oral Abstract # 1005

🙏🏽Thank you @Latinamd @GDutcherMD for an informational & exhilarating #TumorBoardTuesday!!

🏆Remember 🆓CME

Look for the Case Wrap Up🎀 05/26/22

📅Mark your calendar for 𝙉𝙀𝙓𝙏 𝙒𝙀𝙀𝙆 05/31/22 when our own @MPishvaian joins us for a breakdown of #ASCO22 abstracts!! 🏝#TumorBoardTuesday education is beyond Twitter - we offer🆓CME!!

🫁Before you run off exploring, pick up your🏆#CME by answering quick questions regarding a case similar to @Latinamd’s‼️

🔗ALL CME: integrityce.com/tbt

🔗CME eval: integrityce.com/TBTEval

👇🏽🎁

#TumorBoardTuesday

🎓We have had some highly educational🗣️on tumor biomarkers
👍This week’s conversation will NOT disappoint

📢Join us as @Latinamd & @GDutcherMD from @SylvesterCancer discuss MET Exon 14 skip mutations in #NSCLC #Miami #TumorBoardTuesday

@Latinamd & @GDutcherMD @TumorBoardTues 🗣️
📅Tuesday, 05/24/22 at🕗8PM ET
📊✅the polls
⚖️in & bring citations🧾
🔁Retweet & tag your🩺colleagues
🏆Earn your🆓CME and MOC integrityce.com/tbt

And B4⃣the case:
🧐tell us where you are in your🩺journey
👇

1/12 #TumorBoardTuesday
2L treatment in #HER2+ breast cancer #MBC is 🤯! @PTarantinoMD led us through latest evidence👩‍⚖️

➡️Here's the Thurs Case🎀
👉Grab🆓 #CME credit by answering quick❓
ALL CME 🔗: integrityce.com/tbt
CME rationale🔗: bit.ly/3NnreMW
Here we go! 2/12 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:
⬆️ options to tx HER2+ #MBC
✅T-DXd >T-DM1 in 2L setting (DESTINY BREAST-03)
✅Beware ADC tox- think 🫁pneumonitis & GI w T-Dxd
✅ADC design is 🗝:
➡️Need to consider DAR, linker, ability to cause ADCC
✅ADC + IO= open ❓

1/12 #TumorBoardTuesday

🔬🧬Discussion on #ColonCancer and BRAFv600E disease w dMMR led by @FlavioRochaMD
➡️Here is this week's Thurs Case🎀

👉👉 Don’t forget to pick up🆓 #CME credit by answering 2 quick ❓
ALL CME 🔗: integrityce.com/tbt
Now…we’re off to the races! 2/11 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:
#CRC 🚫one disease!
✅Diff 🧬subtypes that define tx sensitivity
✅BRAFv600E is bad–but may be ⬆️sensitive to IO w MLH1 meth
✅Neoadj tx: 🦊FOXTROT= poss benefit, depends on subgroup
✅Keynote177: IO= way to go in dMMR!

😳🤯The hour flew by & none of us noticed!!

🙏🏽 @FogacciJoao for bringing the 🇧🇷 flair to #TumorBoardTuesday & #GastricCancer!!

🏆Remember your🆓CME

Look for Case Wrap Up🎀 04/28/22

📅Mark your calendar for 05/10/22 8pm ET when @FlavioRochaMD joins our #VirtualTumorBoard!! Remember #TumorBoardTuesday education goes beyond Twitter - we offer 🆓 CME!!

Pick up your🏆#CME & NOW #MOC(‼️) by answering quick questions regarding a case similar to @FogacciJoao’s‼️

🔗ALL CME: integrityce.com/tbt

🔗 post rationale: bit.ly/3kcIXdv

🇧🇷🎁🇧🇷

🚨 #CME Thursday 🚨

This week at #TumorBoardTuesday @W_Park_MD discussed FGFR inhibitors in #BiliaryTractCancer #CCA...and how to find FGFR fusions!

Check out the questions below, and tap the link to claim your free #CME...and stay tuned for a special edition of case wrap up! #PostTest Q 1️⃣ #CME #TumorBoardTuesday
👉🏽 ALL CME🔗 integrityce.com/tbt

🤔 What is a molecular biomarker for an FDA approved🎯💊in #Cholangiocarcinoma❓

#OncTwitter #GeneTesting #CCA

1/9 #TumorBoardTuesday Thursday Case Wrap Up🎀

⏰ for #TBT Case Wrap Up!

We looked at dx and tx of Carcinoma of Unknown Primary (#CUP), including how 🧬 can change tx.
There was a lot to learn–we captured what we could of the discussion here:

twitter.com/i/events/15089… 2/9 #TumorBoardTuesday Thurs Case🎀
Take🏠:
#CUP is complicated!
✅Comprehensive approach needed, including:
H&P,🔬, 🩻, 🧬
✅Overall inc of CUP is ⬇️–many liver CUP being recognized as cholangio
✅NGS can help augment the w/u
✅STK11= frequently mut in lung; ⬇️response to IO

1/9 #TumorBoardTuesday Friday Case Wrap Up

🚨Special Friday Edition of #TBT🚨
This week, mgmt of #Pancreatic neuroendo tumors (pNET), led by @nanudasmd. We discussed SOC, role of IO, & brand🆕 💊. Buckle up! We captured the discussion in this moment:

twitter.com/i/events/14995… 2/9 #TumorBoardTuesday Friday Case🎀
Take🏠messages:
We discussed #pNET:
✅Well diff= sens to cape/tem; high% of MGMT methylation -but not predictive of response
✅Tx dictated by disease extent
✅NOT all NETs are ➕ on dotatate! If they are, ☢️PRRT option- but may use late line

#TBTWebinar is back ‼️
🥼 @MPishvaian @BreastCancerMD1 @Latinamd @BenWestphalen

#CME🔗 bit.ly/3vdXBb4
Pretest 👉 bit.ly/3rYNZir
Claim credit 👉 bit.ly/3ljVVXM

Supported by AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc

twitter.com/i/broadcasts/1… #TumorBoardTuesday HER2 #TBTWebinar 🔑

➡️HER2 activity requires receptor dimerization
✅HER1 = EGFR
✅HER3, HER4

➡️HER2 is frequently overexpressed in multiple cancers
✅Protein⬆️due to gene🧬 amplification
✅Constitutive activation due to activating🧬mutation

1/ 🌟 Calling #oncology HCPs 🌟

🆕 #TumorBoardTuesday #Tweetorial
🫁🧬 HER2 in LC
🥼 @MPishvaian & @Latinamd

Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.

CME ℹ️ bit.ly/3ISYLwv

🗣️ Tell us your specialty ‼️ 2/ 🗒️ Full reference list & glossary 👉 bit.ly/3rjoGHz

🔑 Key #CME & faculty info 👇, full info 👉 bit.ly/3ISYLwv

#TumorBoardTuesday

Good Morning #GImedTwitter

🌅🌄🌇Whether you are waking up in San Francisco…..or not (Curse you COVID-19😡)

🧑‍🏫Get ready for 3 packed days of presentations at #GI22

And to get the🧠started, we are going to share our
Top 10 Targeted Therapy Abstracts🎯

#TumorBoardTuesday #TumorBoardTuesday

1⃣/
Once again HER2🎯💊is everywhere #GI22

👉The DESTINY trials have been👍4⃣T-DXd

✅DESTINY-CRC01
➡️T Yoshino, et al "RAPID" Abs 119
⏩53 "Group A" HER2+ RASWT CRC pts
⏩ORR 45%, mOS 15.5 mos
👍Even with prior HER2 Tx
😨But GR>=3 AEs in 65% of pts, 9% ILD

1/ 🌟 Calling #Oncology HCPs 🌟

🆕 #TumorBoardTuesday #Tweetorial #GI22
🧬 HER2 in Gastrointestinal Cancer
👥 @MPishvaian @BenWestphalen

Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.

CME ℹ️ bit.ly/3ruGO07

⁉️ Your specialty 2/ 🗒️ Full reference list & glossary 👉 bit.ly/3tBrmC7

🔑 Key #CME & faculty info 👇, full info 👉 bit.ly/3ruGO07

#TumorBoardTuesday #GI22

1/ 🌟 Calling #Oncology HCPs 🌟

🆕 #TumorBoardTuesday #Tweetorial
🚨 🧬 HER2 in Breast Cancer
👥 @MPishvaian & @ErikaHamilton9

Supported by educational grants from AstraZeneca Pharmaceuticals & Daiichi Sankyo, Inc.

CME ℹ️ bit.ly/3ecVOcC

🗣️ What's your specialty ⁉️ 2/ 🗒️ Full reference list & glossary 👉 bit.ly/3yMvIGW

🔑 Key #CME & faculty info 👇, full info 👉 bit.ly/3ecVOcC

#TumorBoardTuesday

1/9 #TumorBoardTuesday #PostTest Q1️⃣ #CME
Case🎀

@doctorC369 took us on a 🛣️through metastatic #GEA. Lots of pearls🦪 here. First: two ❓...then the wrap up!

🤔These biomarkers are actionable in advanced #EsophagoGastricCancer except…

👉🏽Posttest 🔗: bit.ly/3pKtAvs 2/9 #PostTest Q2️⃣ #CME #TumorBoardTuesday
👉🏽posttest🔗: bit.ly/3pKtAvs

ALL🥇CME🔗: integrityce.com/tbt

🤔 Addition of immunotherapy to chemotherapy in the 1st line Rx of advanced #EsophagoGastricCancer significantly improves PFS and OS PDL1 CPS>1%